IL326390A - Compositions and methods for treatment of spinal muscular atrophy - Google Patents

Compositions and methods for treatment of spinal muscular atrophy

Info

Publication number
IL326390A
IL326390A IL326390A IL32639026A IL326390A IL 326390 A IL326390 A IL 326390A IL 326390 A IL326390 A IL 326390A IL 32639026 A IL32639026 A IL 32639026A IL 326390 A IL326390 A IL 326390A
Authority
IL
Israel
Prior art keywords
compositions
treatment
methods
muscular atrophy
spinal muscular
Prior art date
Application number
IL326390A
Other languages
Hebrew (he)
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of IL326390A publication Critical patent/IL326390A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL326390A 2023-08-10 2024-08-10 Compositions and methods for treatment of spinal muscular atrophy IL326390A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363518796P 2023-08-10 2023-08-10
US202463662509P 2024-06-21 2024-06-21
PCT/US2024/041840 WO2025035143A1 (en) 2023-08-10 2024-08-10 Compositions and methods for treatment of spinal muscular atrophy

Publications (1)

Publication Number Publication Date
IL326390A true IL326390A (en) 2026-04-01

Family

ID=92543299

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326390A IL326390A (en) 2023-08-10 2024-08-10 Compositions and methods for treatment of spinal muscular atrophy

Country Status (3)

Country Link
AU (1) AU2024320694A1 (en)
IL (1) IL326390A (en)
WO (1) WO2025035143A1 (en)

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
JP2002503954A (en) 1997-04-01 2002-02-05 グラクソ、グループ、リミテッド Nucleic acid amplification method
WO1998046728A1 (en) 1997-04-14 1998-10-22 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
WO1999061643A1 (en) 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
US6210892B1 (en) 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
ES2340230T3 (en) 1998-11-10 2010-05-31 University Of North Carolina At Chapel Hill VIRIC VECTORS AND THEIR PREPARATION AND ADMINISTRATION PROCEDURES.
PT1916258E (en) 1999-08-09 2014-07-29 Genzyme Corp Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
US7201898B2 (en) 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
ATE403013T1 (en) 2001-05-18 2008-08-15 Wisconsin Alumni Res Found METHOD FOR SYNTHESIS OF DNA SEQUENCES USING PHOTOLABILE LINKERS
NZ532635A (en) 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
CN1856576B (en) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 Adeno-associated virus (AAV) clades, sequences, vectors containing these sequences and their applications
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
WO2006110689A2 (en) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
EP1777906A1 (en) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Amplitude error compensating apparatus and orthogonality error compensating apparatus
SI2548560T1 (en) 2005-06-23 2015-12-31 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of SMN2 splicing
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
ES2646630T3 (en) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Amino alcoholic lipidoids and uses thereof
PT3305302T (en) 2009-06-17 2018-12-14 Biogen Ma Inc SMN2 EXCISION MODULATION COMPOSITIONS AND METHODS IN A SUBJECT
US20130023033A1 (en) 2010-03-29 2013-01-24 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
PL3586861T3 (en) 2011-06-08 2022-05-23 Translate Bio, Inc. COMPOSITIONS OF LIPID nanoparticles and MRN DELIVERY METHODS
FR2977562B1 (en) 2011-07-06 2016-12-23 Gaztransport Et Technigaz SEALED AND THERMALLY INSULATING TANK INTEGRATED IN A CARRIER STRUCTURE
EA037448B1 (en) 2012-06-08 2021-03-30 Этрис Гмбх METHOD FOR EXPRESSING A THERAPEUTIC mRNA WITH PEI IN LUNG AND PHARMACEUTICAL COMPOSITION
SI2984166T1 (en) 2013-03-15 2020-09-30 The Trustees Of The University Of Pennsylvania Compositions for treating mpsi
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
HK1257801A1 (en) 2015-10-28 2019-11-01 宾夕法尼亚州大学信托人 Intrathecal administration of adeno-associated-viral vectors for gene therapy
WO2017096162A1 (en) 2015-12-02 2017-06-08 Voyager Therapeutics, Inc. Assays for the detection of aav neutralizing antibodies
WO2017100676A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
EP3387138B1 (en) 2015-12-11 2022-01-26 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
US11028372B2 (en) 2015-12-11 2021-06-08 The Trustees Of The University Of Pennsylvania Scalable purification method for AAVRH10
US11015173B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV1
EP3411488A1 (en) 2016-02-03 2018-12-12 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type i
JP7455579B2 (en) 2017-02-28 2024-03-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Novel adeno-associated virus (AAV) clade F vectors and their uses
SG11202006677XA (en) 2018-01-25 2020-08-28 Biogen Ma Inc Methods of treating spinal muscular atrophy
EP3837374A4 (en) 2018-08-15 2022-06-08 Biogen MA Inc. POLYTHERAPY FOR SPINAL MUSCULAR ATROPHY
WO2020132455A1 (en) 2018-12-21 2020-06-25 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
PE20220014A1 (en) 2019-04-29 2022-01-11 Univ Pennsylvania NOVEL AAV CAPSIDES AND COMPOSITIONS CONTAINING THEM
CA3149825A1 (en) 2019-08-08 2021-02-11 Biogen Ma Inc. Potency assays for viral vector production
US20220280548A1 (en) 2019-08-15 2022-09-08 Biogen Ma Inc. Combination therapy for spinal muscular atrophy
US20230304034A1 (en) 2020-05-12 2023-09-28 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
US20230220069A1 (en) 2020-06-17 2023-07-13 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of gene therapy patients
WO2022094078A1 (en) * 2020-10-28 2022-05-05 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
TW202237850A (en) 2020-12-01 2022-10-01 賓州大學委員會 Novel compositions with tissue-specific targeting motifs and compositions containing same
AR125406A1 (en) 2021-04-23 2023-07-12 Univ Pennsylvania NEW COMPOSITIONS WITH SELECTIVE MOTIVES FOR THE BRAIN AND COMPOSITIONS CONTAINING THEM
EP4409010A1 (en) * 2021-10-02 2024-08-07 The Trustees of The University of Pennsylvania Novel aav capsids and compositions containing same

Also Published As

Publication number Publication date
WO2025035143A1 (en) 2025-02-13
AU2024320694A1 (en) 2026-02-12

Similar Documents

Publication Publication Date Title
IL299167A (en) Compositions and methods for treatment of gene therapy patients
EP4126066A4 (en) Compositions and methods of treating muscle dystrophy
IL304612A (en) Synergistic effect of smn1 and mir-23a in treating spinal muscular atrophy
EP4110369A4 (en) Methods of treatment and related compositions
EP4284272A4 (en) Compositions and methods for sustained treatment of pain
CA3251441A1 (en) Use of myostatin inhibitor for treating spinal muscular atrophy
IL289745A (en) Methods of treating or preventing spinal muscular atrophy
IL312583A (en) Composition for treatment and prevention of covid-19
EP4216961A4 (en) Compositions and methods for treatment of coronavirus infection
IL326390A (en) Compositions and methods for treatment of spinal muscular atrophy
CA3299501A1 (en) Compositions and methods for treatment of spinal muscular atrophy
IL321850A (en) Compositions and methods for treating spinal muscular atrophy
IL320242A (en) Compounds and their use for treatment of hemoglobinopathies
CA3280354A1 (en) Compositions and methods for treating spinal muscular atrophy
GB202302434D0 (en) Compositions and method for the treatment of onychomycosis
CA3297342A1 (en) Methods for combination treatment of spinal muscular atrophy
GB2607584B (en) Composition and method of treatment
HK40117406A (en) Compositions and methods for treatment of pain
HK40118662A (en) Compositions and methods for the treatment of spinal muscular atrophy (sma)
GB202318443D0 (en) Compositions and methods of treatment
AU2023900242A0 (en) Combination compositions and methods for treatment of Muscular Dystrophy
GB202218196D0 (en) Compositions and methods of treatment
GB202317378D0 (en) Composition and methods of treatment
CA3270405A1 (en) Compositions and methods for treatment and prevention of pathogens
IL320252A (en) Compositions and methods for treatment and prevention of pathogens